DEC 02, 2021 8:00 AM PST

Early identification of target candidates for pancreatic adenocarcinoma immunotherapy

Sponsored by: Miltenyi Biotec

Event Date & Time
Date:  December 2, 2021
Time: 8:00am (PDT),  11:00am (EDT)
Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput flow cytometry with high-content cyclic immunofluorescence for the early identification of target candidates for cellular immunotherapy. Within this webinar, we aim to guide the viewers through our most recently published scientific findings[1] and related cutting-edge tools, ranging from the preparation of primary and xenografted tumor specimens to the comprehensive antigen screening and deep phenotyping. [1] Schäfer, D., Tomiuk, S., Küster, L.N. et al. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun 12, 1453 (2021).
Learning Objectives
  • Identify the problem of solid tumor CAR T cell therapies in that most identified tumor-associated antigens are also expressed in healthy tissue.
  • Discuss high-throughput flow cytometry followed by high-content immunofluorescent imaging are ideal tools for systematically screening for CAR targets.
  • Discuss how CD318, TSPAN8 and CD66c were identified as potential targets for CAR T cell based immunotherapy of PDAC.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

You May Also Like
Loading Comments...